Balgos A A, Rodriguez-Gomez G, Nasnas R, Mahasur A A, Margono B P, Tinoco-Favila J C, Sansores-Martinez R H, Hassan M, Beppo O, Wongsa A, Cukier A, Vargas F
Department of Medicine, Philippine General Hospital, Manila, Philippines.
Int J Clin Pract. 1999 Jul-Aug;53(5):325-30.
In this double-blind, double-dummy study, 324 patients with clinical evidence of community-acquired pneumonia (CAP) or an acute exacerbation of chronic bronchitis were randomly assigned to receive 10 days' treatment with either amoxycillin/clavulanate 875/125 mg twice daily or amoxycillin/clavulanate 500/125 mg three times daily. At the end of therapy, clinical success rates were 92.4% for the twice daily regimen and 94.2% for the three times daily regimen. There was no statistically significant difference between treatments (p = 0.647) and the 95% confidence interval around the treatment difference indicated that the two treatments were equivalent. Treatment equivalence was also confirmed at follow-up, four weeks after the end of treatment. Both regimens were well tolerated. In conclusion, amoxycillin/clavulanate 875/125 mg twice daily is as effective as amoxycillin/clavulanate 500/125 mg three times daily for the treatment of community-acquired lower respiratory tract infections and could improve patient compliance.
在这项双盲、双模拟研究中，324例有社区获得性肺炎（CAP）临床证据或慢性支气管炎急性加重的患者被随机分配，接受为期10天的治疗，其中一组为阿莫西林/克拉维酸875/125毫克，每日两次；另一组为阿莫西林/克拉维酸500/125毫克，每日三次。治疗结束时，每日两次治疗方案的临床成功率为92.4%，每日三次治疗方案的临床成功率为94.2%。两种治疗方法之间无统计学显著差异（p = 0.647），治疗差异的95%置信区间表明两种治疗方法等效。在治疗结束四周后的随访中也证实了治疗等效性。两种治疗方案耐受性均良好。总之，阿莫西林/克拉维酸875/125毫克每日两次治疗社区获得性下呼吸道感染的效果与阿莫西林/克拉维酸500/125毫克每日三次相当，且可提高患者依从性。
